论文部分内容阅读
目的探究尿激酶治疗心源性脑梗死的临床疗效。方法选取佛山市第二人民医院2011年4月—2014年4月收治的76例心源性脑梗死患者,采用随机数字表法分为观察组与对照组,每组38例。两组患者均进行常规治疗,观察组患者在常规治疗基础上联合尿激酶治疗。比较两组患者临床疗效、神经功能缺损评分及不良反应。结果观察组患者临床疗效优对照组(P<0.05)。两组患者治疗前神经功能缺损评分比较,差异无统计学意义(P>0.05);观察组患者治疗后神经功能缺损评分低于对照组(P<0.05)。两组患者均未发生明显不良反应。结论尿激酶治疗心源性脑梗死的疗效确切,能有效改善神经功能缺损情况,且安全性较高。
Objective To investigate the clinical efficacy of urokinase in the treatment of cardio-cerebral infarction. Methods 76 patients with cardio-cerebral infarction who were admitted to Foshan Second People’s Hospital from April 2011 to April 2014 were randomly divided into observation group and control group with 38 cases in each group. The two groups of patients were treated routinely. Patients in the observation group were treated with urokinase on the basis of routine treatment. The clinical efficacy, neurological deficit scores and adverse reactions were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference between the two groups in the score of neurological deficit before treatment (P> 0.05). The score of neurological deficit in the observation group was lower than that of the control group after treatment (P <0.05). No significant adverse reactions occurred in both groups. Conclusion Urokinase is effective in treating cerebral infarction and can effectively improve the neurological deficit with high safety.